Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

The aryl hydrocarbon receptor links integrin signaling to the TGF-β pathway.

Oncogene·2015
Same author

Pleomorphic xanthoastrocytoma of childhood: MR imaging and diffusion MR imaging features.

AJNR. American journal of neuroradiology·2014
Same author

A deeply seated brain metastasis from a primary myxofibrosarcoma: case report.

Clinical neurology and neurosurgery·2013
Same author

Depletion of the novel p53-target gene carnitine palmitoyltransferase 1C delays tumor growth in the neurofibromatosis type I tumor model.

Cell death and differentiation·2013

Related Experiment Video

Updated: Jul 18, 2026

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
09:39

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1

Published on: February 13, 2018

Mouse tumor model for neurofibromatosis type 1.

K S Vogel1, L J Klesse, S Velasco-Miguel

  • 1Center for Developmental Biology and Department of Pathology, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd., Dallas, TX 75235-9133, USA.

Science (New York, N.Y.)
|December 11, 1999
PubMed
Summary

Neurofibromatosis type 1 (NF1) and p53 gene mutations accelerate tumor development. Mice lacking both Nf1 and p53 genes rapidly develop malignant neural crest tumors, offering insights into NF1 cancer risks.

More Related Videos

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
08:57

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Published on: May 17, 2024

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas
03:53

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas

Published on: October 10, 2025

Related Experiment Videos

Last Updated: Jul 18, 2026

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
09:39

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1

Published on: February 13, 2018

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
08:57

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Published on: May 17, 2024

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas
03:53

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas

Published on: October 10, 2025

Area of Science:

  • Oncology
  • Genetics
  • Developmental Biology

Background:

  • Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder linked to neural crest tumors.
  • Activating ras protooncogene mutations and p53 tumor suppressor gene inactivation are implicated in malignant transformation.

Purpose of the Study:

  • To investigate the synergistic effect of Nf1 and p53 gene mutations on tumor development.
  • To characterize the resulting tumors in a preclinical model.

Main Methods:

  • Generation of mice with combined null alleles for Nf1 and p53.
  • Monitoring tumor incidence and age of onset.
  • Analysis of tumor characteristics, including loss of heterozygosity and phenotypic traits.

Main Results:

  • 100% of mice with cis-acting null Nf1 and p53 alleles developed soft tissue sarcomas between 3-7 months of age.
  • These sarcomas showed loss of heterozygosity at both Nf1 and p53 loci.
  • Tumors exhibited phenotypic traits of neural crest derivatives and human NF1 malignancies.

Conclusions:

  • Loss of Nf1 and p53 function cooperatively drives malignant transformation in neural crest cells.
  • This mouse model accurately recapitulates key features of NF1-associated malignancies.
  • Understanding these genetic interactions is crucial for developing targeted therapies for NF1.